These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 25785725)
1. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725 [TBL] [Abstract][Full Text] [Related]
2. Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug. Hu S; Ferraro M; Thomas AP; Chung JM; Yoon NG; Seol JH; Kim S; Kim HU; An MY; Ok H; Jung HS; Ryu JH; Colombo G; Kang BH J Med Chem; 2020 Mar; 63(6):2930-2940. PubMed ID: 32068404 [TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Gallerne C; Prola A; Lemaire C Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394 [TBL] [Abstract][Full Text] [Related]
4. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. Usmani SZ; Bona RD; Chiosis G; Li Z J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755 [TBL] [Abstract][Full Text] [Related]
5. Crystallization and preliminary X-ray diffraction analysis of Trap1 complexed with Hsp90 inhibitors. Jeong H; Kang BH; Lee C Acta Crystallogr F Struct Biol Commun; 2014 Dec; 70(Pt 12):1683-7. PubMed ID: 25484226 [TBL] [Abstract][Full Text] [Related]
6. Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models. Kim D; Kim SY; Kim D; Yoon NG; Yun J; Hong KB; Lee C; Lee JH; Kang BH; Kang S Bioorg Chem; 2020 Aug; 101():103901. PubMed ID: 32590225 [TBL] [Abstract][Full Text] [Related]
7. TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors. Kang BH BMB Rep; 2012 Jan; 45(1):1-6. PubMed ID: 22281005 [TBL] [Abstract][Full Text] [Related]
8. Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors. Park HK; Jeong H; Ko E; Lee G; Lee JE; Lee SK; Lee AJ; Im JY; Hu S; Kim SH; Lee JH; Lee C; Kang S; Kang BH J Med Chem; 2017 Sep; 60(17):7569-7578. PubMed ID: 28816449 [TBL] [Abstract][Full Text] [Related]
9. 2.4 Å resolution crystal structure of human TRAP1NM, the Hsp90 paralog in the mitochondrial matrix. Sung N; Lee J; Kim JH; Chang C; Tsai FT; Lee S Acta Crystallogr D Struct Biol; 2016 Aug; 72(Pt 8):904-11. PubMed ID: 27487821 [TBL] [Abstract][Full Text] [Related]
10. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting. Rondanin R; Lettini G; Oliva P; Baruchello R; Costantini C; Trapella C; Simoni D; Bernardi T; Sisinni L; Pietrafesa M; Ponterini G; Costi MP; Vignudelli T; Luciani R; Matassa DS; Esposito F; Landriscina M Bioorg Med Chem Lett; 2018 Jul; 28(13):2289-2293. PubMed ID: 29807796 [TBL] [Abstract][Full Text] [Related]
11. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252 [TBL] [Abstract][Full Text] [Related]
12. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy. Li HK; Matsumoto Y; Furusawa Y; Kamada T J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340 [TBL] [Abstract][Full Text] [Related]
13. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Bryant KG; Chae YC; Martinez RL; Gordon JC; Elokely KM; Kossenkov AV; Grant S; Childers WE; Abou-Gharbia M; Altieri DC Oncotarget; 2017 Dec; 8(68):112184-112198. PubMed ID: 29348817 [TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Neckers L; Kern A; Tsutsumi S Chem Biol; 2007 Nov; 14(11):1204-6. PubMed ID: 18022558 [TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate. Sung N; Lee J; Kim JH; Chang C; Joachimiak A; Lee S; Tsai FT Proc Natl Acad Sci U S A; 2016 Mar; 113(11):2952-7. PubMed ID: 26929380 [TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria. Kim H; Yang J; Kim MJ; Choi S; Chung JR; Kim JM; Yoo YH; Chung J; Koh H J Biol Chem; 2016 Jan; 291(4):1841-1853. PubMed ID: 26631731 [TBL] [Abstract][Full Text] [Related]
17. Rational Design of Allosteric and Selective Inhibitors of the Molecular Chaperone TRAP1. Sanchez-Martin C; Moroni E; Ferraro M; Laquatra C; Cannino G; Masgras I; Negro A; Quadrelli P; Rasola A; Colombo G Cell Rep; 2020 Apr; 31(3):107531. PubMed ID: 32320652 [TBL] [Abstract][Full Text] [Related]